Destiny Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Destiny Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200	Closed	-$89.3K	–	1076
2026 Q1	$89.3K	Buy	+200	New	+$93.3K	0.01%	360
2023 Q2	–	Sell	-903	Closed	-$285K	–	195
2023 Q1	$285K	Sell	903 -122	-12%	-$36.6K	0.06%	146
2022 Q4	$296K	Sell	1,025 -41	-4%	-$12.5K	0.06%	158
2022 Q3	$309K	Buy	1,066 +1,037	+3,576%	+$298K	0.07%	120
2022 Q2	$8K	Sell	29 -407	-93%	-$109K	﹤0.01%	470
2022 Q1	$114K	Buy	436 +407	+1,403%	+$96.6K	0.02%	216
2021 Q4	$6K	Hold	29	–	–	﹤0.01%	478
2021 Q3	$5K	Buy	+29	New	+$5.66K	﹤0.01%	464
2021 Q2	–	Sell	-76	Closed	-$16K	–	512
2021 Q1	$16K	Hold	76	–	–	﹤0.01%	378
2020 Q4	$18K	Buy	+76	New	+$17.4K	﹤0.01%	374

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Destiny Wealth Partners's VRTX Position: Q2 2026 in Review

Destiny Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 200 shares — an estimated $89.3K sold.

Destiny Wealth Partners first reported a position in VRTX in Q4 2020 and held it in 10 quarters. The position peaked at $309K in Q3 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Destiny Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Destiny Wealth Partners sold 200 Vertex Pharmaceuticals shares in Q2 2026, an estimated $89.3K.
Destiny Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 10 quarters.
Destiny Wealth Partners's Vertex Pharmaceuticals position peaked at $309K in Q3 2022.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Destiny Wealth Partners's 13F filing for Q2 2026, filed 7 Aug 2026.